Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

NCT02860000 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Estrogen Receptor Status
HER2/Neu Negative
Invasive Breast Carcinoma
Postmenopausal
Stage III Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions

DRUG: Alisertib
DRUG: Fulvestrant
OTHER: Laboratory Biomarker Analysis

Sponsor

Mayo Clinic

Collaborators

[object Object]